Zydus Lifesciences Q3 Review — One Offs Impact Margins; Systematix Recommends 'Hold', Revises Target Price

gAsacol HD which is one of the large products for Zydus in the US market, has started to decline owing to competition (Teva), the impact will be more noticeable in upcoming quarters, says Systematix